Antagonization of Heparin With Protamine Sulfate After TAVI
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 940 participants.
Also called NCT06215378
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 940 participants
- Registry
-
NCT06215378
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT06215378. Randomized; single masking; primary purpose treatment. Start 2025-05-25 (actual); primary completion 2027-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antagonization of Heparin With Protamine Sulfate After TAVI
- Acronym
- ATLANTIS-Prota
- Condition
- Aortic Valve Stenosis
- Condition
- Heart Valve Diseases
- Intervention (Drug)
- Antagonization of heparin with protamine sulfate
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Action Research Group
Record details
- Record id
cardio:ct-nct06215378- Content hash
f6c4a7240bd6e6b7f2c5782cc8d60dbf236f3c1f7ebf437de4e5b11ceeaf8d2d